Is natriuretic peptide lowering strategy superior to symptomatically based management of chronic heart failure with reduced ejection fraction?

2020 ◽  
Vol 79 ◽  
pp. 145-146
Author(s):  
Samarthkumar Thakkar ◽  
Rajkumar Doshi ◽  
Mariam Shariff ◽  
Igor Pedreira Vaz ◽  
Devina Adalja ◽  
...  
2019 ◽  
Vol 74 (9) ◽  
pp. 1205-1217 ◽  
Author(s):  
James L. Januzzi ◽  
Tariq Ahmad ◽  
Hillary Mulder ◽  
Adrian Coles ◽  
Kevin J. Anstrom ◽  
...  

2019 ◽  
Vol 3 (3) ◽  
Author(s):  
Ambre Tiepolo ◽  
Hélène Nougué ◽  
Charles Damoisel ◽  
Jean-Marie Launay ◽  
Nicolas Vodovar ◽  
...  

Abstract Background B-type natriuretic peptide (BNP) and the N-terminal proBNP (NT-proBNP) exhibit different evolution in chronic heart failure patients with reduced ejection fraction treated with Sacubitril/Valsartan; BNP increasing or remaining stable, while NT-proBNP decreases. However, how this difference translates upon acute decompensation is unknown. Case summary Herein, we described in a 78-year-old woman with chronic heart failure with reduced ejection fraction treated with Sacubitril/Valsartan who had acute decompensated heart failure (ADHF). BNP and NT-proBNP were markedly high during ADHF and showed parallel return to baseline level after clinical improvement. Discussion BNP and NT-proBNP retained similar value for the diagnosis of ADHF in patient treated with Sacubitril/Valsartan. These findings strongly suggest that either BNP or NT-proBNP can be used indifferently in this context, while their relative use is debated in chronic heart failure.


2021 ◽  
Vol 23 (7) ◽  
Author(s):  
Sara Rovai ◽  
Irene Mattavelli ◽  
Elisabetta Salvioni ◽  
Ugo Corrà ◽  
Gaia Cattadori ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document